Overview
Kenvue Inc., based in the United States, operates predominantly in the consumer health sector. A spin-off from Johnson & Johnson, the company focuses primarily on manufacturing and selling a variety of healthcare products, including over-the-counter medications, beauty items, and wellness solutions. The strategic intent behind Kenvue’s establishment is to tap into the growing global market for personal health products by leveraging its heritage of trust and science-backed innovations derived from its parent company. Key projects for Kenvue involve expanding market reach both domestically and internationally, enhancing its product portfolio through research and development, and increasing consumer engagement through digital transformation. As a newly independent entity, the company aims to assert its market position by concentrating on core areas of consumer healthcare while pursuing sustainable growth.
AI+ Ask Fintel’s AI assistant about Kenvue Inc..
Thinking about good questions…
Basic Stats
The share price of Kenvue Inc. as of September 5, 2025 is €18.98 / share. This is a decrease of 0.00% from the prior week. The market cap (or net worth) of Kenvue Inc. as of September 5, 2025 is €36,423.37 MM.
The Factor Analysis chart (below right) shows a view of Kenvue Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 36,423.37 MM |
| EV | |
| Shares Out. | 1,918.84 MM |
| Earnings Date | |
| EPS (TTM) | 0.74 |
| Dividend Yield | |
| Ex-Dividend Date | 2025-08-13 |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | 0.13 |
| Beta | 1.02 |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | 0.05 |
| ROE | 0.14 |
| ROIC | 0.07 |
| CROIC | 0.00 |
| OCROIC | 0.11 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | 44.36 /100 |
| Profitability | 63.11 /100 |
| Quality Score | 59.09 /100 |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | 94.17 /100 |
| Analyst Sentiment | |
| Fund Sentiment | 38.98 /100 |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 6.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Kenvue Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2025-07-25 | JP Morgan | Overweight | Overweight | Maintains |
| 2025-05-09 | Citigroup | Neutral | Neutral | Maintains |
| 2025-05-12 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2025-04-14 | Citigroup | Neutral | Neutral | Maintains |
| 2025-04-14 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2025-04-10 | Redburn Atlantic | Neutral | Initiate | |
| 2025-03-27 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2025-03-24 | Evercore ISI Group | In-Line | Initiate | |
| 2025-03-05 | Canaccord Genuity | Buy | Buy | Maintains |
| 2025-02-24 | Piper Sandler | Overweight | Overweight | Maintains |
| 2025-02-07 | UBS | Neutral | Neutral | Maintains |
| 2025-02-07 | Canaccord Genuity | Buy | Buy | Maintains |
| 2025-02-03 | RBC Capital | Sector Perform | Sector Perform | Reiterate |
| 2025-01-17 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2025-01-16 | UBS | Neutral | Neutral | Maintains |
| 2025-01-15 | Citigroup | Neutral | Neutral | Maintains |
| 2025-01-06 | Piper Sandler | Neutral | Overweight | Upgrade |
| 2024-12-13 | Barclays | Equal-Weight | Initiate | |
| 2024-12-12 | Deutsche Bank | Buy | Hold | Downgrade |
| 2024-10-22 | B of A Securities | Buy | Buy | Maintains |
| 2024-10-11 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-09-24 | Jefferies | Buy | Initiate | |
| 2024-09-24 | RBC Capital | Outperform | Sector Perform | Downgrade |
| 2024-09-23 | Piper Sandler | Neutral | Neutral | Maintains |
| 2024-08-07 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-08-07 | Deutsche Bank | Buy | Buy | Maintains |
| 2024-08-07 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-08-07 | UBS | Neutral | Neutral | Maintains |
| 2024-07-25 | Deutsche Bank | Buy | Buy | Maintains |
| 2024-07-22 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-07-10 | Citigroup | Neutral | Neutral | Maintains |
| 2024-05-28 | Citigroup | Neutral | Neutral | Reiterate |
| 2024-05-08 | HSBC | Hold | Hold | Maintains |
| 2024-04-11 | Bernstein | Underperform | Initiate | |
| 2024-04-03 | William Blair | Market Perform | Initiate | |
| 2024-03-04 | Goldman Sachs | Neutral | Neutral | Maintains |
| 2024-03-01 | Goldman Sachs | Buy | Neutral | Downgrade |
| 2024-02-13 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-02-09 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-02-09 | RBC Capital | Outperform | Outperform | Maintains |
| 2023-12-19 | UBS | Neutral | Neutral | Maintains |
| 2023-11-17 | Piper Sandler | Neutral | Initiate | |
| 2023-10-10 | Goldman Sachs | Buy | Buy | Maintains |
| 2023-10-04 | JP Morgan | Overweight | Overweight | Maintains |
| 2023-09-11 | Deutsche Bank | Hold | Buy | Upgrade |
| 2023-09-07 | Canaccord Genuity | Buy | Initiate | |
| 2023-09-06 | Argus Research | Hold | Initiate | |
| 2023-08-24 | Goldman Sachs | Neutral | Buy | Upgrade |
| 2023-08-17 | RBC Capital | Outperform | Outperform | Reiterate |
| 2023-07-25 | Edward Jones | Buy | Initiate | |
| 2023-07-21 | Citigroup | Neutral | Neutral | Maintains |
| 2023-06-01 | HSBC | Hold | Initiate | |
| 2023-05-30 | UBS | Neutral | Initiate | |
| 2023-05-30 | B of A Securities | Buy | Initiate | |
| 2023-05-30 | RBC Capital | Outperform | Initiate | |
| 2023-05-30 | JP Morgan | Overweight | Initiate | |
| 2023-05-30 | Goldman Sachs | Neutral | Initiate | |
| 2023-05-30 | Deutsche Bank | Hold | Initiate | |
| 2023-05-30 | Citigroup | Neutral | Initiate | |
| 2023-05-30 | Exane BNP Paribas | Neutral | Initiate | |
| 2025-08-08 | RBC Capital | Sector Perform | Sector Perform | Maintains |
| 2025-05-09 | UBS | Neutral | Neutral | Maintains |
| 2025-07-17 | UBS | Neutral | Neutral | Maintains |
| 2025-08-08 | Canaccord Genuity | Buy | Buy | Maintains |
| 2025-07-15 | Citigroup | Neutral | Neutral | Maintains |
| 2025-07-15 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2025-07-15 | B of A Securities | Buy | Buy | Maintains |
